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Targeted DNA degradation using a CRISPR device
stably carried in the host genome
Brian J. Caliando1 & Christopher A. Voigt1
Once an engineered organism completes its task, it is useful to degrade the associated DNA
to reduce environmental release and protect intellectual property. Here we present a
genetically encoded device (DNAi) that responds to a transcriptional input and degrades
user-deﬁned DNA. This enables engineered regions to be obscured when the cell enters a
new environment. DNAi is based on type-IE CRISPR biochemistry and a synthetic CRISPR
array deﬁnes the DNA target(s). When the input is on, plasmid DNA is degraded 108-fold.
When the genome is targeted, this causes cell death, reducing viable cells by a factor of 108.
Further, the CRISPR nuclease can direct degradation to speciﬁc genomic regions (for example,
engineered or inserted DNA), which could be used to complicate recovery and sequencing
efforts. DNAi can be stably carried in an engineered organism, with no impact on cell growth,
plasmid stability or DNAi inducibility even after passaging for 42 months.
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T
he ability to programme cells to eliminate engineered DNA
at a deﬁned time point or change in environments would
beneﬁt many applications in biotechnology. For example,
after bio-manufacturing a chemical, cells could be programmed
to degrade their DNA at the end of the process or when they are
removed from a deﬁned medium. This would aid the protection
of sequence information as a trade secret, make it easier to
remove DNA contamination from a product, reduce the cost of
biomass disposal and decrease the amount of DNA in the
environment after an accidental release. There are similar needs
for ‘out of the bioreactor’ applications, such as using engineered
cells as living therapeutics (for example, in the gut microbiome)
or in forming associations with crop plants in a ﬁeld1. In these
cases, it is impossible to recollect cells for disposal, so they need to
be programmed to degrade their own DNA when they leave a
deﬁned environment or after a deﬁned time period.
Various genetic switches have been developed that induce cell
death2. The actuation is based on toxic proteins that are under
tight regulatory control to avoid background expression3–4 and
have been combined with synthetic genetic circuits that trigger
cell death under a shift in environmental conditions or change in
cell state5–9. Inducing cell death does not address the problem of
the release of DNA, which persists after cells die or are killed.
Indeed, waste streams from fermenters are rich with recombinant
DNA, even when the cells have been inactivated by heat, pH and
antibiotics10 and, in fact, these methods of rapid cell death
exacerbate the release of extracellular DNA11. The waste biomass
of engineered microbes is often used as agricultural fertilizer (for
example, NovoGro), and this has been shown to contain
signiﬁcant amounts of DNA10. Furthermore, DNA molecules
are stable and, once introduced, plasmid and genomic DNA can
be recovered from environmental samples via PCR for 1–5
months11,12 and is likely to be detectable longer with advances in
deep sequencing13. In one study, 35% of plasmid DNA molecules
that were exposed to the extreme heat and pressures of
atmospheric re-entry on the surface of a rocket still retained
their biological function14.
The ease of recovering DNA from environmental samples
poses a challenge for the biotech industry. First, the value and
competitive advantage of a company is largely in its engineered
DNA constructs and strains and these involve large ﬁnancial
investments and development time. Protecting this information
as a trade secret is nearly impossible when samples can be easily
recovered from a waste stream (or as a contaminant in a
consumer product), sequenced and then rebuilt using chemical
DNA synthesis. Therefore, the copying of the products of genetic
engineering no longer requires the transfer or theft of intact DNA
molecules or living cells. In the future, it may be possible to access
complete organisms through the synthesis and transplantation of
entire genomes15–17.
Once DNA is stably introduced into cells, removing it is
tedious and difﬁcult to scale to an industrial process. The
traditional way to remove plasmids is to ‘cure’ them by culturing
on non-selecting media over multiple generations18. Another
method is to express nonspeciﬁc DNA nucleases, which efﬁciently
cause cell death (1:105, ref. 8), but their nonspeciﬁcity can
severely inhibit cell growth even when maintained in the
uninduced state2. DNA can also be removed via downstream
processing of the fermentation product or waste streams. This is
necessary for the production of therapeutic proteins and DNA
(for gene therapy and vaccines), where the US Food and Drug
Administration enforces allowable limits for contaminant DNA
(10 ng per dose)19,20. This either requires high-performance
puriﬁcation methods and/or removal of DNA speciﬁcally via ion
exchange columns or membrane ﬁltration, all of which are
expensive and difﬁcult to implement19–21.
The RNA guide-directed DNAse machinery from type-I, -II
and -IIIA CRISPR defense systems22 provides a means to remove
DNA by directing nuclease activity to target sequences. CRISPR is
an ‘immune system’ for prokaryotes that prevents transduction
by phage and conjugative plasmids by targeting their DNA for
degradation22–24. The targeted DNA sequences are speciﬁed by
the CRISPR array, which is a series of B30–40 bp spacers
separated by short palindromic repeats22–24. The array is
transcribed as a pre-crRNA and is processed into shorter
crRNAs that associate with the Cas protein complex to target
complementary DNA sequences known as proto-spacers25–33.
These proto-spacer targets must also have an additional
neighbouring sequence known as a proto-spacer adjacent motif
(PAM) that is required for target recognition33–38. After binding,
a Cas protein complex serves as a DNA endonuclease to cut both
strands at the target32,33 and subsequent DNA degradation occurs
via exonuclease activity32. The RNA-guiding capability of the Cas
protein(s) has been widely applied to problems in biotechnology,
including genome editing and synthetic regulation39–45.
There are several advantages to using the CRISPR nuclease to
remove intracellular DNA. First, the guide sequences can be
used to direct nuclease activity to user-deﬁned DNA targets
with high speciﬁcity. This can be used to knock out plasmids
without harming the host or to target speciﬁc sensitive regions
of the genome. Second, it can target multiple sequences in
parallel. Finally, it has shown to be functional in many cell
types, including eukaryotes and higher organisms. We selected
the Type-IE CRISPR system native to K-type Escherichia coli,
which has been shown to inhibit phage infection25,38,46,47,
cure plasmids 32,44,48, prevent conjugal element transfer49 and
kill cells45,50.
Here, we describe the construction of a genetic device (DNAi)
whose input is a transcriptional signal and whose output is the
CRISPR-mediated targeted degradation of DNA (Fig. 1a). Deﬁn-
ing a transcriptional input enables it to be connected to the
output of inducible systems, environmental sensors or genetic
circuits51. Modularized component design enables rapid
reprogramming of the device’s output to degrade any user-
speciﬁed set of DNA targets. The device stably maintains all of the
necessary components for DNAi-mediated nuclease activity and,
on induction, degrades the target DNA while leaving non-
targeted DNA unaffected. This requires the device to retain a
large dynamic range when induced, yet have almost no basal
activity when carried in the host genome in the uninduced state.
We demonstrate that the DNAi device is effective at knocking out
plasmid targets with a wide range of copy numbers quickly and
efﬁciently. We also show that DNAi activity renders the targeted
DNA sequence information more difﬁcult to recover via PCR
ampliﬁcation, that alternative PAM sequences can be used to tune
the device’s kinetic proﬁle, and that targeting DNAi activity to the
host chromosome enables highly efﬁcient inducible cell killing.
Furthermore, when passaged in the off state, the device does not
impose an appreciable growth burden on the host, remains stable
and active over many generations and does not affect protein
expression from the target DNA before induction.
Results
Design and optimization of the DNAi device. The design for the
DNAi device is shown in Fig. 1a. The transcriptional input
induces an operon containing the cas3 and casABCDE genes25.
These genes are normally transcribed separately, but we
combined them so that a single promoter could serve as the
device input. The combined activities of Cas3 and the CasABCDE
complex are analogous to Cas9, which is the basis for CRISPRi
and genome editing. We chose the former because we
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hypothesized they could be less toxic in gram-negative hosts and
unlike Cas9, Cas3 possesses 30-to-50 helicase52 and ssDNA
exonulease activities53, which could enhance DNA degradation
after the initial cleavage event. The DNA targeting information is
in the form of a synthetic CRISPR array, composed of an
alternating sequence of 29-bp repeats, which contain the
recognition site for CasE-mediated crRNA processing, separated
by 32-bp unique spacer sequences (Supplementary Table 1). The
array is constitutively expressed from the weak PJ23117 promoter.
The cas actuator and targeting array can be carried on plasmids
or the genome and remain functional (Supplementary Figs 1b, 2a,
3 and 4). For the work in this manuscript, the actuator is carried
in the genome (Supplementary Table 2) to reduce background
activity and the array is carried on a high-copy pUC19 plasmid to
reduce loss-of-function mutations and to simplify the testing of
different targets.
The input promoter serves as the master switch. We chose to
characterize the device using the arabinose-inducible PBAD
promoter because it has a tight OFF state while maintaining a
large dynamic range. Transcriptional activity from this promoter
is turned on upon the addition of arabinose to the media and
turned off with the addition of glucose. In theory, any promoter
could be connected to the device that spans the required range of
promoter activity (Supplementary Fig. 5). This could be an
environmental sensor that responds to a particular media or
growth phase, or the output of a genetic circuit that processes a
more complex combination of sensory inputs. The activator for
PBAD is the AraC protein and a loss-of-function mutation in the
Input
[arabinose]
DNAi device
PJ23117 Spacer Repeat
CasE
CRISPR
crRNA guides
Target DNA
RFP
ori
PAM
+
Target degraded
Proto-spacer
StrR
StrR
ori
CasABCDE Cas3
CmR
colE1
AraC
Actuator
3
PBAD
CRISPR
RFP
Target
plasmid
Y 10
0
100
10–2
10–2
1012
Time post-activation (h)
0 2 4 6 8
1010
1010
Ab
so
lu
te
 c
op
y 
nu
m
be
r
(co
pie
s p
er 
ml
 cu
ltu
re)
108
106
104
N
10–4
10–4
Fr
ac
tio
n 
ta
rg
et
+
 
ce
lls
Fr
ac
tio
n 
ta
rg
et
+
 
ce
lls
10–6
10–6
10–8
10–8
OFF
pBAC target pSC101 target p15A target pUC19 target
ON
OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON OFF ON
OFF ON OFF OFF OFFON ON ON OFF ON OFF ON
N Y Z Y+Z
Y+Z N Y+Z N Y+Z N Y+Z
Y Z Y+Z
1x 1x 1x 3x 3x 3x1x
DNAi
spacer
actuator
DNAi
spacer
Z
N
Z Y
Y+Z
E. coli genome
A B C D E
cas genes
pBAC
pSC101
p15A
pUC19
Figure 1 | Characterization of the DNAi device. (a) A schematic of the device (dashed box) is shown. The CRISPR array is transcribed from a constitutive
promoter (PJ23117). (b) The Y and Z spacers are designed to be internal to the Str
R gene carried on the targeted plasmid. The N spacer is a control whose
sequence is not present in the targeted plasmid or genome. The spacer sequences and the PAMs associated with their corresponding proto-spacers are
presented in Supplementary Table 1. (c) Data for the knockout of target plasmids are shown for different spacers and numbers of actuators carried in the
genome (1x and 3x). The fraction of cells that retain the pSC101 origin pTAR(S) target plasmid (Targetþ ) is shown in the OFF (repressed by 0.5% glucose)
and ON (2mM arabinose) states. The OFF data and the 1x/N ON data were obtained using the cytometry assay and the remainder were obtained by the
plate-based assay (Methods). (d) A time course is shown for the knockout of target plasmids containing different origins of replication. The inducer
(2mM arabinose) is added at t¼0h and aliquots of each sample are removed over time and analysed using the plating assay to determine the fraction
retaining the target plasmid (Methods). The vertical dashed line indicates t¼ 2.25 h, the time at which the PBAD promoter activates to initiate the synthesis
of DNAi actuator components (Supplementary Fig. 5a). All of the data were gathered using the 3x DNAi device and the YþZ dual spacers. When the
target contains the pUC19 origin, the plasmid containing the targeting array was changed to a compatible RSF origin (pCR-YZ* and pCR-N*). (e) The
recovery of target plasmid DNA sequences via PCR after the 8-h induction of DNAi as performed in d is quantiﬁed via qPCR and is given in terms of
absolute copy number per millilitre of culture (ACNculture; Methods). All data represent the average of three independent experiments performed on
different days and the error bars are the s.d.
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corresponding gene would cause the DNAi device to fail. To
hedge against this, up to three redundant copies of araC are
expressed from the genome (Methods).
A plasmid-based target pTAR(S) was designed to test and
optimize the device (Fig. 1b). Initially, a low copy origin was
selected (pSC101, 10–12 copies) to increase sensitivity to leakage
in the OFF state. The plasmid also contains a dual-phenotype
reporter system (streptomycin resistance and red ﬂuorescent
protein, RFP) to quantify the presence or absence of the target
plasmid in a population using either plate assays or ﬂow
cytometry (Methods). To test the DNAi device, we designated a
proto-spacer target sequence (Y) that was already present in the
wild-type StrR coding region of the plasmid and possessed a
native 50-ATG PAM (Fig. 1b). A second spacer was designed as a
negative control (N) that lacks any identity to the target plasmid
or host genome. An E. coli strain containing a single genomic
copy of the actuator (1x) was transformed with either the Y- or
N-targeting plasmid. The cells were then grown in the presence
(ON) or absence (OFF) of arabinose without antibiotic selection
for the target plasmid ( spectinomycin, Methods). When the Y
spacer is included, the plasmids are lost in all but 0.009% of
the population (Fig. 1c). Importantly, this only occurs when the
device is ON and no plasmid is lost when it is maintained in the
OFF state. As expected, transcribing the off-target N spacer does
not lead to any plasmid loss when the device is either in the ON
or OFF state.
We sought to engineer the system to improve the efﬁciency at
which the targeting plasmid is degraded. First, we changed the
proto-spacer target to a different sequence within the StrR gene
(Z) that possesses a native 50-AAG PAM. This target alone or in
combination with the Y spacer yielded the same reduction in the
target plasmid (Fig. 1c). However, when combined with a strain
that includes the actuator at three locations in the genome (3x),
the inclusion of two targets (YþZ) improved the degradation
104-fold, reducing the fraction of the cells carrying the plasmid to
2.1 10 9, which is equivalent to o30 colony forming units
(c.f.u.) per ml. The increase in the number of copies of the
actuator in the genome did not impact the level of
the background activity, where 498% of the cells retained the
plasmid when the actuator is carried in the OFF state. This is in
contrast to what is observed when the actuator is carried on a
plasmid system, where even low copy number backbones resulted
in signiﬁcant plasmid loss (Supplementary Fig. 4).
It is interesting that the additional spacer only improves
efﬁciency for the 3x copy of the actuator, but does not improve
efﬁciency when the strain carries only one copy (1x). To
determine the cause of this effect, we characterized escape
mutants to determine where mutations had occurred to disrupt
DNAi activity (Supplementary Fig. 6). We found that for the 1x
strain, the dominant type of escape mutation disrupted the
actuator and only a relatively small fraction of mutations
disrupted the spacer or proto-spacer target. Thus, adding a
second spacer is of limited help. However, for the 3x strain, no
escape mutations involved mutation of the actuator and all
occurred in the spacer. Because mutation of the spacer is now
limiting, the addition of a second spacer further improves the
efﬁciency. Thus, under these conditions, the device’s knockout
efﬁciency is ultimately dictated by the single component that is
most likely to fail. Adding redundancy lowers the probability that
individual components will fail, but doing so merely re-
establishes a new efﬁciency ﬂoor based on the next most
failure-prone candidate.
Next, the optimized DNAi device was assayed for its ability to
knock out plasmids with varying copy numbers. These target
plasmids were constructed by substituting the pSC101 origin of
replication (10–12 copies per genome, Fig. 1b) with either a
pBAC (one to two copies per genome), p15A (20–30 copies per
genome) or pUC19 (4500 copies per genome) origin54–56. The
target plasmids were transformed into E. coli containing the 3x
DNAi device and a targeting array with both the Y and Z spacers.
Cells were induced with 2mM arabinose and plasmid loss was
measured periodically over 8 h (Fig. 1d). The dynamics were
surprisingly independent of copy number. Once the PBAD
promoter turns on after B2 h (Supplementary Fig. 5a), there is
a sudden drop in plasmid abundance followed by a slower decay.
At steady-state, there is only a 1.8-fold difference in the residual
presence of plasmid from the high-copy pUC19 (1.2 10 9) to
the single-copy pBAC (7.1 10 10). We next examined the
ability of DNAi to render the target plasmid DNA sequence more
difﬁcult to recover via PCR-based methods. After 8 h of
induction, total plasmid DNA was isolated from each sample
using a Qiagen miniprep, and quantitative PCR (qPCR) was used
to quantify the amount of recoverable target DNA (Methods).
Figure 1e shows how the absolute copy number of the recovered
DNA sequence changes when the device is turned ON for the
targets containing different origins of replication. Upon
activation, the device dramatically diminishes the amount of
DNA that can be recovered. The amount of residual DNA that
remains after induction reﬂects the copy number of the target.
Upon DNAi activation, all of the targets exhibit a fairly constant
fold reduction of B104. As expected, there is no appreciable
reduction in the amount of PCR-recoverable DNA when the off-
target N spacer is used. The DNAi device has no impact on the
plasmid copy number when the device is carried in the OFF state.
This can be seen for each target by comparing the amount of
recoverable DNA between the N and YþZ spacers for each of
the plasmid targets (Fig. 1e).
In addition to spacer complementarity, DNAi also requires a
valid 3-bp 50 PAM sequence35,37,38. Others’ experiments with
phage transfection assays had identiﬁed four functional PAM
sequences (50-AAG, -AGG, -ATG and -GAG)32. We sought to
determine whether additional 3-bp sequences could serve as
active PAMs when used with our device. This would increase the
range of potential target sequences, such that they would not be
required to start with one of these four options. Serendipitously,
we also discovered that the selection of the PAM sequence
impacts the kinetics of DNA degradation. Preliminary
experiments identiﬁed 10 strong PAMs (that include the known
four) and ﬁve weak PAMs (Supplementary Figs 7 and 8), and so a
set of RFPþ target plasmids (pSC101 origin, StrR) was
constructed on the basis of the X proto-spacer coupled to each
of these 15 PAM sequences, in addition to a 50-CCG negative
control (Fig. 2a). A plasmid knockout experiment was then
performed with the 1x DNAi device, an X-targeting CRISPR
plasmid and each of these PAM-coupled target plasmids (Fig. 2b,
Supplementary Fig. 9, Methods). There was a wide spread in the
kinetics of plasmid loss (Fig. 2c), with AAG corresponding to the
fastest knockout and GGG corresponding to the slowest. The lag
phase before initiation of target loss ranged from 160min (AAG)
to 300min (GGG), and the associated half-lives of decay ranged
over two orders of magnitude from 2.1min (AAG) to 363min
(GGG). Collectively, this expanded PAM set will allow designers
to target the greatest possible range of native sequences, will
enable more comprehensive prediction of possible off-target
interactions and will allow tailoring of DNAi kinetics from
minutes to hours. This would enable different DNA sequences to
be targeted at different times; for example, targeting plasmids ﬁrst
followed by the genome and the DNAi device itself.
Genetic stability of the DNAi device. To be used effectively, the
device must be silently carried in the OFF state and not slow
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growth, lower plasmid copy number or reduce the function of the
engineered organism (for example, product yield). Toxicity could
arise from the cas genes, where off-target nuclease activity could
manifest as slower growth. To determine the toxicity of the
ON state, we grew cells in different concentrations of inducer
continuously for 8 h and then measured viable cell titre (in c.f.u.
per ml) (Fig. 3a). The measurements were based on the 3x
actuator and contained the YþZ dual spacers and the targeting
plasmid, which was being knocked out during the time course.
Activity was well tolerated at the inducer concentrations used for
the experiments in this manuscript (2mM). Even upon maximal
induction (10mM), o40% reduction in culture density was
observed. Furthermore, the rate of cell growth was minimally
affected as well. When analogous growth rate measurements were
performed comparing the 3x DNAi strain to the actuator-free
strain, the maximal difference in doubling time was o1.5min
(Supplementary Fig. 10a). This is in contrast to when the cas
genes are carried on a plasmid, where even a single-copy BAC
actuator can result in a signiﬁcant reduction in growth
(Supplementary Fig. 10b).
If the DNAi device has activity in the OFF state, then this could
cause selective pressure against its own maintenance. This could
lead to loss-of-function mutations that degrade activity over time.
In the short-term growth experiments (Fig. 3a), we did not
observe a decrease in cell density in the absence of inducer. Still,
the effect could be subtle and the device could break when carried
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over a long period. To test this, cells containing the 3x device, the
YþZ spacer array and the pSC101 target plasmid were passaged
in the OFF state for 90 days (Fig. 3b). During this time course,
cells were passaged every 12 h into fresh media with selection for
the target plasmid (þ spectinomycin). Because the cells are
maintained under conditions favouring cell growth, this time
course involves a remarkable 1,700 cell divisions, corresponding
to a 10520-fold ampliﬁcation of the initial inoculant. Every 2 days,
a sample of the culture was removed and subjected to the plasmid
knockout experiment (Fig. 1c and Methods). Over the entire time
course, the plasmids are consistently lost such that they only exist
in an average of 2.1 10 8 of the cell population (Fig. 3b). The
stability of target plasmid protein expression levels over the entire
course of the experiment was also conﬁrmed by quantifying the
RFP signal (Supplementary Fig. 11).
Programmed cell death by targeting DNAi to the host genome.
The expression of nucleases that degrade the host genome leads
to cell death8,40,44,45,50,57,58. To determine whether the DNAi
device could be used to induce cell death, we constructed host
strains containing the 3x device with targeting plasmids encoding
a genome-targeted spacer (either G1 or G2) or an off-target spacer
(N, Fig. 4a). The G2 spacer targets the attL sequence present in all
three of the actuators, which are separated by chromosomal
distances of 300 kbp and 2.8Mbp, respectively. The G1 spacer was
selected to target only a single chromosomal sequence that is
directly adjacent to the actuator at the DCRISPR-cas locus. Both
the G1 and G2 spacers are oriented such that their respective
crRNAs base pair with the genomic ( ) strand upon target
recognition.
Strains containing G1, G2 or N were induced with 2mM
arabinose (DNAi ON) or repressed with 0.5% glucose (DNAi
OFF, Fig. 4b). Over an 8-h period, the ratio of viable cells for each
spacer was measured as the cell titre of the corresponding strain
in the ON state divided by that of the strain in the OFF state
(Methods). For both the strains containing G1 or G2, when the
DNAi device is turned ON, cell death is very rapid following a lag
phase that is analogous to that observed for the plasmid
knockouts (Fig. 1d). The spacer corresponding to multiple sites
in the genome is more effective at killing cells, leveling off at a
viable cell ratio of 1.9 10 8, which corresponds to 80 c.f.u. per
ml. When the DNAi device is OFF (0.5% glucose), no cell death is
observed after 8 h (Supplementary Fig. 12). This is consistent with
the long-term plasmid stability that is observed when a targeting
spacer is carried but the device is OFF (Fig. 3b). Together, these
observations highlight the negligible leakage of the device and its
ability to be carried without imparting its activity until induced,
even when carrying a toxic genome-targeted spacer.
One advantage of using speciﬁc endonucleases is that particular
regions of the genome can be targeted for degradation. This could
be used to preferentially remove DNA associated with a highly
engineered region or insertions containing synthetic pathways.
Because the exonuclease activity chews the DNA from either end
of the cut, it is expected that there will be less recoverable DNA
around the region of the targeted sequence. We applied qPCR to
test this using the G1 spacer, which is centred on position
2,887,466 of the E. coli str. K-12 genome (NCBI numbering), and
compared it with the control (N). Samples were induced and
qPCR was used to amplify ﬁve genomic loci at different distances
from the G1 cut site (Fig. 4c, Methods). The amount of DNA
remaining from the region surrounding the target (0–1 kb) is
reduced 4103-fold. By 10 kb, there isB3.3-fold more DNA, but
there is still signiﬁcant loss. Notably, the DNAi device is carried
within 10 kb of each G2 spacer. This is a demonstration of the
system exhibiting targeted degradation of its own genetics. By
Chromosomal targets
+1
*
*oriC
1 Mbp
100 kbp
10 kbp
*
E. coli str. K-12
MG1655
G2
G1
G1
CRISPR
G2
G2 N
Time post-activation (h)
0
100
10–2
10–4
10–6
10–8
100
10–1
10–2
R
el
at
iv
e 
co
py
 n
um
be
r r
at
io
(D
NA
i O
N/
OF
F)
10–3
10–4
Spacer
Dist. to G1
N
0 bp 1 kbp 10 kbp 100 kbp 1 Mbp
R
at
io
 c
el
ls
 (D
NA
i O
N/
OF
F)
2 4 6 8
G2
G1 N G1 N G1 N G1 N G1
Figure 4 | Degradation of speciﬁc genomic regions via DNAi and the induction of cell death. (a) Two on-target spacers (G1 and G2) are shown along
with the locations of their corresponding sequences in the E. coli K-12 host chromosome. The G2 spacer targets a site within the chromosomally inserted
actuator sequences (starred) and so those proto-spacer locations coincide with the three actuator locations. An off-target spacer (N) is used as a control
as it does not target a sequence in the genome. The spacing from the G1 target for the qPCR assays is shown. (b) The kinetics of cell killing is shown, where
the efﬁciency is presented as a ratio of the titre of viable cells between the DNAi ON (þ 2mM arabinose) and OFF (þ0.5% glucose) states. The data are
shown for the 3x actuator and the G1 (pCR-G1) or G2 (pCR-G2) targets (green diamonds and orange squares, respectively). The N control (pCR-N) is
shown as blue circles. The vertical dashed line indicates t¼ 2.25 h, the time at which the PBAD promoter activates to initiate the synthesis of DNAi actuator
components (Supplementary Fig. 5a). The corresponding viable cell titre measurements are shown in Supplementary Fig. 12. (c) The ability to recover
chromosomal DNA sequences via PCR after the induction of DNAi for 8 h is quantiﬁed as a function of distance (dist.) from the single chromosomal
proto-spacer target. For each chromosomal locus, the efﬁciency of recovery is measured as the ratio of the relative copy number (RCN) of the DNAi ON
state divided by that of the corresponding DNAi OFF state (Methods). Chromosomal distances are measured as the centre-to-centre spacing between
the PCR amplicon indicated and the singly occurring G1 chromosomal protospacer (NCBI NC_000913.3 position 2,887,466). Sequences for primer pairs
are provided in Supplementary Table 5. All data represent the average of three independent experiments performed on different days and error bars
indicate the s.d.
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1Mb, the amount of DNA equals that which is recoverable from
the N control. This demonstrates that the speciﬁcity of the Cas
complex can be applied to selectively target regions of the genome
while leaving non-targeted regions intact.
Discussion
We have demonstrated that the CRISPR machinery can be used
to degrade speciﬁc intracellular DNA in an inducible and targeted
manner. When a plasmid is targeted, it is rapidly lost from a
population, and when the genome is targeted, this results in rapid
cell death. The DNAi device is non-toxic when carried in the
genome, is stable for months and does not impart background
activity until induced. This stability does not come at a cost of
effectiveness. Indeed, the ability to reduce the number of viable
cells by 1.9 10 8 is among the most effective switches for
programmed cell death reported to date59 and many of these
other systems impart a load on the cell.
An industrial accident could release 1017–1019 cells into the
environment12. In such a scenario, the reduction of viable cells by
a factor of 1.9 10 8 is equivalent to reducing the viable cells in
a 1M litre fermenter to those present in 19ml of culture. This is
well below the log 6 reduction in viable cells in the liquid/solid
waste stream required by the US Environmental Protection
Agency and close to the log 8 reduction required by the US
National Institutes of Health (NIH) E. coli host-vector (EK2)
guidelines60 for plasmid retention before disposal. DNAi is also
able to degrade plasmid and genomic DNA by 108-fold and the
target speciﬁcity of the CRISPR machinery allows the nuclease
activity to be targeted to recombinant DNA or regions desired to
be undetectable. Whether due to accidental release or the use of
biomass as fertilizer, the extracellular DNA eventually decays
because of nucleases produced by the soil microbiota11.
Experiments with recombinant E. coli showed that DNA could
be detected by PCR for 28–60 days after release with half-lives (t1/
2) of days, with large variation due to soil type and
environment11,12. Beginning with 108-fold less DNA reduces
the detection time by B27t1/2, which can reduce the detection
time from months to days.
Historically, biology’s capacity to replicate and propagate its
DNA has been exploited to procure genetically modiﬁed samples
without the developer’s consent. During the 1950s and 1960s, at
the height of phage research, investigators toyed with the idea of
obtaining samples of mutant phage variants from competing
groups by swabbing the letters and envelopes used for written
correspondence between the two labs61. In the past, withholding
DNA constructs from competitors outright or through a
restrictive material transfer agreement was common, but
advances in DNA synthesis have made it trivial to bypass these
barriers. In a case of industrial espionage, a researcher was
convicted in 2011 for the theft of trade secrets from Dow
Agrosciences and Cargill and their transfer to competing
corporate and academic interests62. The theft involved the
physical transfer of strains as well as an electronic DNA
sequence for a proprietary enzyme, with the associated loss
valued at $7 million (USD)62.
This manuscript introduces a genetic device that is able to
degrade targeted DNA upon the activation of a transcriptional
input. For environmental and intellectual property applications,
the input could be changed to connect to sensors that activate
when the cells are removed from a deﬁned media or exposed to
particular conditions (for example, light or oxygen). More
sophisticated control can be achieved by connecting the device
to the output promoter of a transcriptional genetic circuit; for
example, genetic logic to integrate signals from multiple sensors
that deﬁne a cocktail of chemicals speciﬁc to a media or
environment59,63. Similar control could be implemented for
applications that make use of the ability of the device to target-
speciﬁc DNA while leaving the remainder intact. For example,
enzymes encoded on a plasmid could be permanently eliminated
at a late stage of fermentation. The DNAi device enables these
functions while being carried silently in the host genome before
activation. Furthermore, the DNAi device is compatible with
other systems for the containment of genetically modiﬁed
organisms, including devices that implement programmed cell
death, DNA deletion and the re-coding of the genome to require
non-natural amino acids59,64. One can imagine combining these
systems to create layers of redundancy to ensure that engineered
organisms are viable in particular environments and if they
escape, they eliminate their synthetic DNA.
Methods
Strains and media. All strains were derived from a triple-knockout E. coli
MG1655 D(araC-araBAD) DPlacI:LacI D(cas3-CRISPR) parent (Supplementary
Table 2). Standard plasmids were cloned and propagated using an E. coli
Mach1-T1R host (F j80(lacZ)DM15 DlacX74 hsdR(rKmKþ ) DrecA1398 endA1
tonA; Life Technologies), while plasmids containing an R6Kg origin of replication
were cloned and propagated using an E. coli TransforMax EC100D pir-116 host
(F mcrA D(mrr-hsdRMS-mcrBC) j80dlacZDM15 DlacX74 recA1 endA1 araD139
D(ara, leu)7697 galU galK l- rpsL (StrR) nupG pir-116(DHFR)) (Epicenter). Cells
were plated on LB (LB Miller Medium, Difco, #244620) supplemented with 1.5%
(w/v) agar (Bacto Agar, Difco, #214010), and liquid cultures were grown in 2YT
media (2xYT (Yeast Extract Tryptone) Medium, Difco #244020) for all experi-
ments. Ampicillin (100 mgml 1; sodium ampicillin, Gold Biotechnology #A-301-
25), kanamycin (50 mgml 1; kanamycin sulfate, Gold Biotechnology #K-120-10),
spectinomycin (100 mgml 1; spectinomycin dihydrochloride, Gold Biotechnology
#S-140-5) and/or chloramphenicol (35 mgml 1; USB #23600-25G) were used as
appropriate. L-arabinose (Ara; Sigma-Aldrich #A3256-100G) or glucose (Glc; BDH
#BHD8005-500G) was used as inducer or repressor, respectively.
Strain construction. Genomic knockouts were performed via the lRED method
using a linear kanamycin-resistant cassette ampliﬁed from pKD13 (ref. 65,
Supplementary Table 3). Knock-ins of the B11 kb DNAi actuator plasmids
(pACT-01 and -02, Supplementary Fig. 1b) or their ﬂuorescence measurement
plasmids (pGFP-01 and pGFP-02, Supplementary Fig. 1c) were achieved by
adapting high-efﬁciency site-speciﬁc chromosomal integrations66. First, the
Streptomyces phage PhiK38 1 attB site67 (Supplementary Fig. 1a, Supplementary
Table 4) was inserted into the host chromosome via the lRED method. Next, the
linked KanR marker was removed via pCP20 (ref. 65), and the resulting attBþ
KanS host was transformed with a temperature-sensitive plasmid (pInt5ts, AmpR)
expressing the cognate phage integrase Int5 under the control of a PBAD
promoter67 (Supplementary Fig. 1a). Transformants carrying the integrase plasmid
were grown in 2YT containing ampicillin and 1mM arabinose in a shaking
incubator at 30 C and 250 r.p.m. to an OD600B0.5, at which point
electrocompetent cells were prepared. The resulting Int5-expressing cells were
transformed with an integrative actuator plasmid (pACT-01 or pACT-02, KanR,
non-replicative R6Kg origin) containing the PhiK38–1 attP site via electroporation
and subsequently recovered in 2YT at 37 C for 3 h. Recombinants were selected
for by growth on LB plates containing kanamycin at 37 C. Successful
chromosomal integration at the targeted locus was conﬁrmed with colony PCR,
and loss of the temperature-sensitive Int5 expression plasmid was conﬁrmed by
AmpS phenotype. For each modiﬁed genomic locus, a corresponding donor strain
in a wild-type MG1655 background was created. These antibiotic marker-linked
loci were then serially transferred to the ﬁnal recipient host via P1vir viral
transductions68. Finally, the genomically integrated FRT-ﬂanked R6Kg origin and
kanamycin resistance marker was removed by expression of FLP recombinase
following transformation with temperature-sensitive plasmid pCP20 (AmpR,
CmR)65. Loss of the FRT-ﬂanked region and curing of pCP20 was subsequently
conﬁrmed by colony PCR and the presence of KanS, AmpS and CmS phenotypes.
The 1x DNAi device contains the pACT-01 actuator chromosomally integrated at
the native CRISPR-cas locus. The 3x DNAi device contains the pACT-01 actuator
chromosomally integrated at the LacI locus, and the pACT-02 actuator integrated
at the araC-araBAD and CRISPR-cas loci (Supplementary Tables 2 and 3). The 3x
GFP strain was constructed identically, except with pGFP-01 or pGFP-02
chromosomally integrated in lieu of pACT-01 or pACT-02, respectively. Each copy
of the actuator or GFP plasmid is associated with its own copy of the araC gene,
which is under control of either its native PC promoter (pACT-01) or a constitutive
PJ23117 promoter (pACT-02).
Preparation of phagemid virion stock solutions. The viral origin of replication
(bp 5,505–5,811) was deleted from M13KO769 to create M13Dori (KanR, p15A),
a packaging-defective viral helper plasmid that enables the packaging and secretion
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of phagemids supplied in trans but is incapable of infectious self-propagation.
MG1655 (F ) cells were contransformed with M13Dori and either a pPAM-TC
(RFP , StrR) or a pPAM-NNN (64 PAM library, RFP , StrR) target plasmid.
Single colonies were selected by growth on kanamycin and spectinomycin, and
were used to inoculate 2YT containing the appropriate antibiotics. Samples were
grown for 24 h at 37 C at 250 r.p.m. The cultures were centrifuged at 4,000g at
4 C, and the virion-containing supernatant was washed with chloroform, cen-
trifuged again at 4,000g, and the virion-containing aqueous layer was extracted.
High levels of RFP expression from pPAM-NNN-RFP in combination with M13
viral protein expression are lethal to the host, and so these plasmids could not be
similarly packaged in this manner.
Plate-based plasmid knockout assay. Host cells containing a DNAi device and an
RFPþ target plasmid (StrR) were transformed with a CRISPR targeting plasmid
(CmR), plated onto LB containing all appropriate antibiotics in addition to 0.5%
glucose and grown for 12h at 37 C. Single colonies were used to inoculate 2YT
(1ml) containing all appropriate antibiotics and 0.5% glucose, and the resulting
liquid cultures were grown in a shaking incubator for 3 h at 37 C and 250 r.p.m. until
OD600¼ 0.25–0.75. Cultures were spun down at 21,000g, washed once with fresh
2YT (1ml) and back-diluted to OD600¼ 0.01 into 2YT (2ml) containing appropriate
antibiotics but without selection for the target plasmid ( spectinomycin). The
diluted culture was then split into two 1ml samples, and DNAi activity was either
induced by adding 2mM arabinose or repressed by adding 0.5% glucose. Cultures
were then grown in a shaking incubator for 8 h at 37 C and 250 r.p.m. and peri-
odically sampled. The fraction of host cells retaining the target plasmid (Targetþ )
was calculated from the ratio of colony forming units obtained from plating onto
both target-selective (þ spectinomycin) and non-selective ( spectinomycin) LB
plates containing all other appropriate antibiotics. In our hands, the plate-based assay
was imprecise for measuring samples expected to contain a high fraction (450%) of
target-positive host cells (that is, DNAi OFF or off-target CRISPR samples). A
cytometry-based assay was used for precise quantiﬁcation of these samples (see
Cytometry-based plasmid knockout assay (RFP) below).
Cytometry-based plasmid knockout assay. Samples were prepared and induced
identically to the plate-based knockout assay described above, except that for
sampling, aliquots were back-diluted 1:1,000 into 2YT containing 0.5% Glc and all
appropriate antibiotics except spectinomycin, and then outgrown in a shaking
incubator at 37 C and 250 r.p.m. for 8–12 h. This served to arrest further target
plasmid loss while allowing for the dilution of accumulated intracellular RFP in the
target-negative cells present. Following outgrowth, aliquots were diluted into PBS
containing 1mgml 1 kanamycin to arrest further growth and protein synthesis
and stored at 4 C. Cells were analysed using a BD Biosciences LSRFortessa. The
fraction of cells containing the target plasmid was calculated as fraction of cells
with red ﬂuorescence values greater than a 1,000 arbitrary units cut-off. Data were
analysed using FlowJo (TreeStar Inc., Ashland, OR), and populations were gated on
the basis of forward and side scatter. For all samples, the gated population con-
tained between 104 and 105 cells.
Plasmid knockout kinetic assay (PAM experiments). Samples were prepared as
for the plate-based knockout assay, except the sample volumes were reduced to
500ml and all cultures were grown in 96-well format in a shaking incubator at
37 C and 990 r.p.m. Cultures were sampled and subsequently outgrown as
described for the cytometry-based knockout assay. For targets with strong PAM
sequences (AAA, AAC, AAG, AAT, AGG, ATG, GAG or TAG), experiments were
carried out for 4.5 h with sampling every 10min beginning at 2 h post induction.
For targets with slow (CAG, GGG, GTG, TAA or TAG) or intermediate (ATA or
TTG) PAM sequences, experiments were carried out for 8 h with sampling every
15min starting at 3 h post induction. Following outgrowth, aliquots were diluted
into PBS containing 1mgml 1 kanamycin to arrest further growth and protein
synthesis and stored at 4 C. Cells were analysed using a BD Biosciences
LSRFortessa. Data were analysed using FlowJo (TreeStar Inc., Ashland, OR) and
populations were gated on the basis of forward and side scatter. For all samples, the
gated population contained between 104 and 106 cells.
Isolation of target plasmid DNA. Following a plasmid knockout experiment,
500ml of the resulting culture was collected and spun down at 21,000g, and the
supernatant was removed and discarded. Any resulting pellets were stored at
 20 C until isolation could be performed in parallel. For plasmid knockout
samples, plasmid DNA extraction was performed using a miniprep kit (Qiagen)
and all samples were normalized to a ﬁnal volume of 100ml of EB (Qiagen) for
subsequent qPCR analysis. On the basis of experiments in which comparable
samples of target-negative cells were doped with known amounts of gel-puriﬁed
target plasmid (pTAR(S)) and then subjected to analogous DNA extraction tech-
niques, the efﬁciency of miniprep isolation was estimated at 35±18%.
Isolation of target chromosomal DNA. A 250-ml aliquot of the culture was
collected and spun down at 21,000g, and the supernatant was removed and dis-
carded. Any resulting pellets were stored at  20 C until isolation could be
performed in parallel. Total genomic DNA was extracted using a Wizard Genomic
DNA Puriﬁcation Kit (Promega) in accordance with the manufacturer’s protocol,
and all the samples were resuspended in a ﬁnal volume of 100 ml of TE buffer
(Promega) for subsequent qPCR analysis. The efﬁciency of total genomic DNA
isolation was calculated to be 14±3.0% by generating qPCR standard curves from
known quantities of target DNA and assuming one copy of the genome per c.f.u.
and 3 109 c.f.u. per 250 ml sample.
Quantitative PCR. Quantitative PCR reactions (10ml total) containing 1ml of
either sample or standard DNA template were prepared from SsoFast EvaGreen
Supermix with Low ROX (Bio-Rad) in accordance with the manufacturer’s speci-
ﬁcations. The samples were ampliﬁed and measured using a Mastercycler RealPlex2
(Eppendorf) real-time PCR thermocycler. The thermocycling protocol (40 cycles)
was as follows: (1) initial denaturation—2:00 at 95 C; (2) melting—0:03 at 95 C; (3)
annealing/synthesis: 0:30 at 65 C. Primers and amplicons are described in
Supplementary Table 5, and all primers ampliﬁed their targets with 100±5%
efﬁciency. For each amplicon, a series of 5-fold serial dilutions was prepared from a
1 ngml 1 stock solution of gel-puriﬁed target DNA. Each of the eight dilutions
spanning 5 1 to 5 8 ngml 1 was then subjected to measurement by qPCR in
triplicate, and the resulting Ct values were used to prepare a calibration curve of Ct
versus relative copy number (RCN), for which the most dilute solution
(5 8 ngml 1) was arbitrarily designated as RCN¼ 1. When absolute quantiﬁcation
was required, a sample’s RCN value was determined using the calibration curve and
subsequently converted to an absolute copy number (ACNsample; given in copies per
ml sample) value using the formula ACN¼RCN (6.02 1023 copiesmol 1)
 (5 8 ngml 1 sample)/M, where M is the molecular weight of the speciﬁc dsDNA
amplicon (in ngmol 1, Supplementary Table 5). The isolated DNA samples
loaded into the qPCR reactions were more concentrated relative to the initial
cultures from which they were obtained, and so ACNsample was then converted to
ACNculture (given in copies per ml culture) according to the formula ACNculture¼
ACNsample (1,000ml ml 1)/C, where C is equal to the initial volume of culture
sampled divided by the ﬁnal volume of the isolated DNA sample. For miniprepped
DNA (500ml culture into 100 ml EB) C¼ 5, and for isolated genomic DNA (250ml
culture into 100ml TE) C¼ 2.5.
Measuring the impact on cell growth. Strains containing variants of the DNAi
devices were co-transformed with both a target plasmid and a corresponding on-
target CRISPR plasmid, plated onto LB containing antibiotics in addition to 0.5%
glucose, and grown for 12 h at 37 C. Single colonies were used to inoculate 2YT
(1ml) containing all appropriate antibiotics and 0.5% Glc, and the resulting liquid
cultures were grown in a shaking incubator for 3 h at 37 C and 250 r.p.m. until
OD600¼ 0.25–0.75. Cultures were spun down at 21,000g, washed once with
fresh 2YT (1ml), diluted to OD600¼ 0.01 into 2YT (3ml) containing kanamycin
and/or chloramphenicol as appropriate and then split into 3 1ml samples in a
96-well format. Each sample was induced with Ara (0, 2 or 10mM) and then
grown in a shaking incubator for 8 h at 37 C and 250 r.p.m. The viable cell titre of
each sample was then measured by plating serial dilutions onto non-selective
( spectinomycin) LB plates containing all other appropriate antibiotics.
Evolutionary stability experiments. The strain containing the 3x DNAi device
was transformed with the on-target YþZ dual CRISPR plasmid (pCR-YZ, CmR)
and a pSC101 target plasmid (pTAR(S), RFPþ , StrR), plated onto LB containing
chloramphenicol and spectinomycin in addition to 0.5% Glc, and grown for 12 h at
37 C. A single colony was used to inoculate 2YT (1ml) containing chlor-
amphenicol, spectinomycin and 0.5% Glc (‘cell passage media’), and the resulting
liquid culture was grown for 3 h in a shaking incubator at 37 C and 250 r.p.m. until
OD600¼ 0.25–0.75. These cells were washed with 2YT (1ml), and then back-
diluted to OD600¼ 10 5 into fresh cell passage media (1ml) to mark the start of
the experiment (‘day 1’, t¼ 0). The culture was grown continuously in a shaking
incubator at 37 C and 250 r.p.m. with back-dilution to OD600¼ 10 5 (75,000- to
100,000-fold) into fresh cell passage media (1ml) occurring every 12±2 h. In
parallel with every fourth such back-dilution (corresponding to a B48-h period)
beginning with the ﬁrst occurring at t¼ 0 measurements of DNAi device knockout
efﬁciency and target plasmid stability were performed on a sample removed from
the passaged culture in accordance with aforementioned protocols (see both
‘Plasmid knockout assay’ sections above). Continuous culture and periodic
measurement of the sample were performed in this manner for a period of
90 days.
Cell death assays. The strain containing the 3x DNAi device was transformed
with either an on-target (pCR-G1 or -G2, CmR) or an off-target CRISPR targeting
plasmid (pCR-N2, CmR), plated onto LB containing chloramphenicol in addition
to 0.5% Glc, and grown for 12 h at 37 C. Single colonies were used to inoculate
2YT (1ml) containing chloramphenicol and 0.5% glucose, and the resulting liquid
cultures were grown in a shaking incubator for 3 h at 37 C and 250 r.p.m. until
OD600¼ 0.25–0.75. Cultures were spun down at 21,000g, washed once with fresh
2YT (1ml) and back-diluted to OD600¼ 0.01 into 2YT (2ml) containing chlor-
amphenicol. The diluted culture was then split into two 1-ml samples, and DNAi
activity was either induced by adding 2mM arabinose (DNAi ON) or repressed by
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adding 0.5% glucose (DNAi OFF). Cultures were then grown in a shaking incu-
bator for 8 h at 37 C and 250 r.p.m. with periodic removal of samples for analysis.
For each sample, the titre of viable cells (in c.f.u. per ml) was then determined by
10-fold serial dilution and subsequent plating onto LB agar containing chlor-
amphenicol. The fraction of viable cells was then calculated as the ratio of the cell
titre in the DNAi ON state to that in the DNAi OFF state for a given CRISPR
target.
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